ClinicalTrials.gg
CompletedNCT05522439Updated May 28, 2025

A Study to Evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients With Eosinophil Phenotype

A Phase 2 interventional study of SHR-1703 and SHR-1703 Placebo in Asthma With Eosinophilic Phenotype, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-05-28.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
85
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Asthma by Jiangsu HengRui Medicine Co., Ltd. — 5 open to participants now, 6 under way, 2 of them phase 3. Asthma · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
7th of 15
85 · median 84
Started
2022
the only one that year
Phase 2
6 of 15
3 open now
Registered
7th of 15
by date

Among the 15 studies in Asthma by Jiangsu HengRui Medicine Co., Ltd., this one is the 7th largest by enrollment, is the only one that started in 2022, is one of 6 in phase 2, and was the 7th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

5 of the 15 studies in Asthma by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Asthma by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients with Eosinophil Phenotype.

03

Conditions studied

  • Asthma With Eosinophilic Phenotype

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 to 75years (inclusive).
  2. Weight ≥40 kg.
  3. History of asthma≥ 1 year.
  4. Documented treatment with Medium or high daily dose inhaled with additional controller medication within the 3 months prior to randomization.
  5. Previously confirmed history of one or more asthma exacerbations within 1 year prior to randomization.
  6. Blood eosinophils of ≥150 cells/µL at screening and baseline.
  7. Pre-Bronchodilator % pred≥40% and\<80% at screening and baseline.
  8. Asthma Control Questionnaire-6 score≥1.5.
  9. Use highly effective measures.
  10. Willing to sign the form to participate in this study.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with pulmonary diseases;
  2. Subjects with other diseases that could lead to elevated eosinophils;
  3. Subjects with Immunodeficiency;
  4. Poorly controlled hypertension;
  5. Subjects with severe cerebrovascular disease;
  6. Subjects with infection history requiring clinical intervention;
  7. Subjects with parasitic infection;
  8. Diagnosed Malignant tumor within 5 years prior to randomization;
  9. Used non-selective β-blockers within 1 week prior to randomization;
  10. Used either 5-lipoxygenase inhibitor or Phosphodiesterase-4 inhibitor within 1 week prior to randomization;
  11. Blood donation or massive blood loss, or transfusion of blood products or immunoglobulins within 4 weeks prior to randomization;
  12. inoculated within 4 weeks before randomization;
  13. Allergen Immunotherapy within 8 weeks prior to randomization;
  14. Used systemic or immunomodulators, or biologics or Th2 cytokine inhibitors within 12 weeks prior to randomization or within 5 half-lives of the drug;
  15. Bronchial thermoplasty within 1 year prior to randomization;
  16. Subjects have planned Surgery or other medical procedures that may affect evaluation during the study period;
  17. Subjects with significant laboratory abnormality at screening;
  18. Subjects have prolonged or other abnormality with significant safety risk at screening;
  19. Current smokers or ex-smokers who have given up smoking for \<6 months ,or positive smoke test, and/or have a smoking pack history of > 10 pack years;
  20. History of drug or substance abuse or alcohol abuse within 1 year prior to screening;
  21. Subjects participated another clinical studies and received active drug within 30 days or 5 half-lives prior to screening;
  22. Subjects is pregnant, lactating,or planning to become pregnant;
  23. Subjects have a known history of or intolerance to anti-IL-5 mabs or other biological agents;
  24. Other conditions unsuitable for participation in the study per investigator judgement.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
85 participants (actual)

Study arms

  • Experimental
    Subjects receiving SHR-1703 dose 1

    Drug: SHR-1703 · Drug: SHR-1703 Placebo

  • Experimental
    Subjects receiving SHR-1703 dose 2

    Drug: SHR-1703

  • Experimental
    Subjects receiving SHR-1703 dose 3

    Drug: SHR-1703 · Drug: SHR-1703 Placebo

  • Placebo comparator
    Placebo

    Drug: SHR-1703 Placebo

Interventions

  • SHR-1703 will be administered by SC injection.

  • DrugSHR-1703 Placebo

    Matching Placebo will be administered by the SC route.

06

What researchers measure

Primary outcomes

  1. Changes from baseline in Blood Eosinophils

    Time frame: Up to Week 52

Secondary outcomes

  1. Changes from baseline in Pre- and post-Bronchodilator FEV1

    Time frame: Up to Week 52

  2. Changes from baseline in Pre- and post-Bronchodilator FEV 1% pred

    Time frame: Up to Week 52

  3. Changes from baseline in Pre- and post-Bronchodilator FVC

    Time frame: Up to Week 52

  4. Changes from baseline in Pre- and post-Bronchodilator PEF

    Time frame: Up to Week 52

  5. Changes from baseline in n fractional exhaled nitric oxide (FeNO)

    Time frame: Up to Week 52

  6. Changes from baseline in Asthma Control Questionnaire-6(ACQ-6)

    Time frame: Up to Week 52

  7. Changes from baseline in Standardized Asthma Quality of Life Questionnaire (AQLQ)

    Time frame: Up to Week 52

  8. Frequency of use of asthma relievers

    Time frame: Up to Week 24

  9. Frequency of exacerbations of asthma

    Time frame: Up to Week 24

  10. Frequency of severe exacerbations of asthma

    Time frame: Up to Week 24

  11. Time to first exacerbation of asthma

    Time frame: Up to Week 24

  12. Time to first severe exacerbation of asthma

    Time frame: Up to Week 24

07

Study locations

1 site
  • West China Hospital of Sichuan University
    Chengdu, Sichuan 610041, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Sep 2024, 20 months.

Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 20 months is above that.

Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2022
First posted
Aug 31, 2022
StartActual
Dec 22, 2022
Primary completionActual
Sep 12, 2024
CompletionActual
Sep 12, 2024
Last update
May 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05522439
Responsible party
Sponsor
First posted
Aug 31, 2022
Start date
Dec 22, 2022
Primary completion
Sep 12, 2024
Completion
Sep 12, 2024
Last update
May 28, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR-1703

Start the discussion